• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Targeting the PI3K signaling pathway in cancer therapy
【24h】

Targeting the PI3K signaling pathway in cancer therapy

机译：在癌症治疗中靶向PI3K信号通路

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: The PI3K signaling pathway is involved in the regulation of cancer cell growth, motility, survival and metabolism. The pathway is frequently active in many different types of cancer-e.g., breast, bladder, prostate, thyroid, ovarian and NSCLC. Targetable genetic aberrations in this pathway give us many opportunities for development of targeted therapies for different types of cancer. Areas covered: The genetic alterations in the PI3K/mammalian target of rapamycin (mTOR)/Akt pathway, as well as the drugs that target this pathway, either alone, in combination with other targeted agents or in chemotherapy. Targeted inhibitors of the PI3K pathway currently being tested in clinical trials in different types of human cancer. Expert opinion: Small-molecule inhibitors targeting the PI3K/Akt/mTOR pathway show some success with these agents in current clinical trials. For further improvement in response, molecular correlates that can be used for patient selection, need to be determined. A more efficient and effective way to screen for patients to determine which patients are most likely to benefit from PI3K pathway inhibitors is also needed.
机译：简介：PI3K信号通路参与癌细胞生长，运动，存活和代谢的调节。该途径经常在许多不同类型的癌症中活跃，例如乳腺癌，膀胱癌，前列腺癌，甲状腺癌，卵巢癌和NSCLC。该途径中的可靶向遗传畸变为我们提供了许多机会，可针对不同类型的癌症开发靶向疗法。涵盖的领域：PI3K /雷帕霉素（mTOR）/ Akt途径的哺乳动物靶标以及靶向该途径的药物的遗传学改变，既可以单独使用，也可以与其他靶向药物联合使用，也可以在化学疗法中使用。 PI3K途径的靶向抑制剂目前正在不同类型的人类癌症的临床试验中进行测试。专家意见：针对PI3K / Akt / mTOR途径的小分子抑制剂在目前的临床试验中显示出这些药物的某些成功。为了进一步改善反应，需要确定可用于患者选择的分子相关性。还需要一种更有效的方法来筛选患者，以确定哪些患者最有可能受益于PI3K途径抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号